SHELLEY WRAY: Open Payments
NPI 1447649975 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$367 in 12 payments from 9 companies in 2025. Trend: 2023 $226 · 2024 $701 · 2025 $367
Food & beverage: $367
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 2 | $128 |
| Biogen, Inc. | 1 | $70 |
| Neurocrine BioSciences, Inc. | 2 | $32 |
| ABBVIE INC. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
Products named: LYBALVI, ZURZUVAE, INGREZZA, VRAYLAR, AUSTEDO XR, CAPLYTA, REXULTI, Jornay PM.
Industry payments across ID — which companies pay providers there.
